180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced the filing of a provisional patent describing the novel combination of cannabidiol (“CBD”), or an analog thereof, with glucagon related peptide-1 (“GLP-1”) agonists to address obesity and weight management. Co-administration of CBD, a known appetite suppressant and antiemetic, might be expected both to limit the harmful side effects and lower the effective dosage of the GLP-1 agonists. “We are excited about the opportunity to collaborate with scientists who are experts in vagus nerve signaling,” said Dr. James Woody, CEO of 180 Life Sciences. “We expect, if the hypothesis is correct, this research could provide support to proceed to human clinical trials. Our Chief Scientific Officer Dr. Jonathan Rothbard was involved in the amylin discovery work of the GLP-1 pathway and has extensive scientific knowledge of how synthetic CBD compounds might induce satiety through stimulating the vagus nerve.”
To view the full press release, visit https://ibn.fm/7asyw
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs, which are seeking to address major unmet needs. The company’s primary focus is a novel program to treat inflammatory disorders using anti-TNF (tumor necrosis factor) biologics. In addition, the company is exploring the anti-inflammatory and analgesic properties of synthetic CBD compounds, which also might be effective in appetite suppression.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
